Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH
Go back to Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH| Johnson & Johnson (NYSE: JNJ) | Delayed: 240.87 +2.54 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $238.33 | 52 Week High | $126.07 | |||
| Open | $240.00 | 52 Week Low | $94.28 | |||
| Day High | $240.91 | P/E | 50.08 | |||
| Day Low | $237.52 | EPS | $4.81 | |||
| Volume | 6,459,367 | |||||
